Do advanced glycation end-products cause food allergy?

Current Opinion in Allergy and Clinical Immunology

Volumn 17, Issue 5, 2017, Pages 325-331

  Smith, Peter K ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

advanced glycation end products; high molecular group box 1; N(6) carboxymethyllysine; receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; HIGH MOLECULAR GROUP BOX 1 PROTEIN; LIGAND; PROTEIN; PROTEIN S 100; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; VITAMIN D; ALARMIN; ALLERGEN;

ADAPTIVE IMMUNITY; CELL ACTIVATION; DEGRANULATION; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; EPIDEMIOLOGICAL DATA; EPITHELIUM; EVIDENCE BASED PRACTICE; FOOD ALLERGY; GLYCATION; HUMAN; INNATE IMMUNITY; LABORATORY TEST; MICROFLORA; NONHUMAN; POPULATION; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; AUSTRALIA; CROSS REACTION; DIET; DISEASE MODEL; IMMUNOLOGY; MOLECULAR MIMICRY; PREVALENCE;

ALARMINS; ALLERGENS; ANIMALS; AUSTRALIA; CROSS REACTIONS; DIET; DISEASE MODELS, ANIMAL; FOOD HYPERSENSITIVITY; GLYCATION END PRODUCTS, ADVANCED; HUMANS; MOLECULAR MIMICRY; PREVALENCE;

EID: 85028641975     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000385     Document Type: Review

References (99)

1. Prescott SL, Pawankar R, Allen KJ, et al. A global survey of changing patterns of food allergy burden in children. World Allergy Organ J 2013; 6: 1.
2. Strachan DP. Hay fever, hygiene, and household size. BMJ 1989; 299: 1259-1260.
3. Gruber C. Prevention of allergy by pro-and prebiotics. Expert Rev Clin Immunol 2009; 5: 1-3.
4. Cahenzli J, Koller Y, Wyss M, et al. Intestinal microbial diversity during early-life colonization shapes long-term IgE levels. Cell Host Microbe 2013; 14: 559-570.
5. Prescott SL, Bjorksten B. Probiotics for the prevention or treatment of allergic diseases. J Allergy Clin Immunol 2007; 120: 255-262.
6. Prescott SL, Smith P, Tang M, et al. The importance of early complementary feeding in the development of oral tolerance: concerns and controversies. Pediatr Allergy Immunol 2008; 19: 375-380.
7. Du Toit G, Roberts G, Sayre PH, et al. Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med 2015; 372: 803-813
8. Kuo CH, Hsieh CC, Kuo HF, et al. Phthalates suppress type I interferon in human plasmacytoid dendritic cells via epigenetic regulation. Allergy 2013; 68: 870-879.
9. Allen KJ, Koplin JJ, Ponsonby AL, et al. Vitamin D insufficiency is associated with challenge-proven food allergy in infants. J Allergy Clin Immunol 2013; 131: 1109-1116.
10. Lack G. Update on risk factors for food allergy. J Allergy Clin Immunol 2012; 129: 1187-1197.
11. Silverberg JI, Simpson EL, Durkin HG, Joks R. Prevalence of allergic disease in foreign-born American children. JAMA Pediatr 2013; 167: 554-560.
12. Koplin JJ, Peters RL, Ponsonby A-L, et al. and the HealthNuts Study Group. Increased risk of peanut allergy in infants of Asian-born parents compared to those of Australian-born parents. Allergy 2014; 69: 1639-1647.
13. Panjari M, Koplin JJ, Dharmage SC, et al. Nut allergy prevalence and differences between Asian-born children and Australian-born children of Asian descent: a state-wide survey of children at primary school entry in Victoria, Australia. Clin Exp Allergy 2016; 46: 602-609
14. Mehr S, Frith K, Campbell DE. Epidemiology of food protein-induced enterocolitis syndrome. Curr Opin Allergy Clin Immunol 2014; 14: 208-216.
15. Dellon ES. Epidemiology of eosinophilic esophagitis. Gastroenterol Clin North Am 2014; 43: 201-218.
16. Hong X, Tsai HJ, Wang X. Genetics of food allergy. Curr Opin Pediatr 2009; 21: 770-776.
17. Tan TH, Ellis JA, Saffery R, Allen KJ. The role of genetics and environment in the rise of childhood food allergy. Clin Exp Allergy 2012; 42: 20-29.
18. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007; 81: 1-5.
19. Vistoli G, De Maddis D, Cipak A, et al. Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation. Free Radic Res 2013; 47(Suppl 1): 3-27.
20. Ansari NA, Moinuddin. Ali R. Glycated lysine residues: a marker for nonenzymatic protein glycation in age-related diseases. Dis Markers 2011; 30: 317-324.
21. Ott C, Jacobs K, Haucke E, et al. Role of advanced glycation end products in cellular signaling. Redox Biol 2014; 2: 411-429.
22. Fritz G. RAGE: a single receptor fits multiple ligands. Trends Biochem Sci 2011; 36: 625-632.
23. SimsGP, Rowe DC, Rietdijk ST, et al. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010; 28: 367-388.
24. Sparvero LJ, Asafu-Adjei D, Kang R, et al. RAGE (receptor for advanced glycation endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med 2009; 7: 17.
25. Uribarri J, Cai W, Sandu O, et al. Diet derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. Ann N Y Acad Sci 2005; 1043: 461-466.
26. Ramasamy R, Vannucci SJ, Yan SS, et al. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 2005; 15: 16R-28R.
27. Chilelli NC, Burlina S, Lapolla A. AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: a 'glycoxidationcentric' point of view. Nutr Metab Cardiovasc Dis 2013; 23: 913-919.
28. Nicholl ID, Stitt AW, Moore JE, et al. Increased levels of advanced glycation end products in the lenses and blood vessels of cigarette smokers. Mol Med 1998; 4: 594-601.
29. Bierhaus A, Schiekofer S, Schwaninger M, et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2011; 50: 2792-2808.
30. Kislinger T, Fu C, Huber B, et al. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 1999; 274: 31740-31749.
31. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005; 5: 331-342.
32. Lander HM, Tauras JM, Ogiste JS, et al. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogenactivated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997; 272: 17810-17814.
33. Dumitriu IE, Baruah P, Bianchi ME, et al. Requirement of HMGB1 and RAGE for the maturation of human plasmacytoid dendritic cells. Eur J Immunol 2005; 35: 2184-2190.
34. Dumitriu I, Baruah P, Valentinis B, et al. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol 2005; 174: 7506-7515.
35. Messmer D, Yang H, Telusma G, et al. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol 2004; 173: 307-313.
36. He Z, Shotorbani SS, Jiao Z, et al. HMGB1 promotes the differentiation of Th17 via up-regulating TLR2 and IL-23 of CD14 monocytes from patients with rheumatoid arthritis. Scand J Immunol 2012; 76: 483-490.
37. Sundberg E, Fasth AER, Palmblad K, et al. High mobility group box chromosomal protein 1 acts as a proliferation signal for activated T lymphocytes. Immunobiology 2009; 214: 303-309.
38. Li G, Liang X, Lotze MT. HMGB1: the central cytokine for all lymphoid cells. Front Immunol 2013; 4: 68.
39. Yanai H, Ban T, Taniguchi T. High-mobility group box family of proteins: ligand and sensor for innate immunity. Trends Immunol 2012; 33: 633-640.
40. Morbini P, Villa C, Campo I, et al. The receptor for advanced glycation end products and its ligands: a new inflammatory pathway in lung disease? Mod Pathol 2006; 19: 1437-1445.
41. Huang W, Zhao H, Dong H, et al. High-mobility group box 1 impairs airway epithelial barrier function through the activation of the RAGE/ERK pathway. Int J Mol Med 2016; 37: 1189-1198
42. Raman KG, Sappington PL, Yang R, et al. The role of RAGE in the pathogenesis of intestinal barrier dysfunction after hemorrhagic shock. Am J Physiol Gastrointest Liver Physiol 2006; 291: G556-G565.
43. Leibold JS, Riehl A, Hettinger J, et al. Keratinocyte-specific deletion of the receptor RAGE modulates the kinetics of skin inflammation in vivo. J Invest Dermatol 2013; 133: 2400-2406.
44. Yan SF, Yan SD, Ramasamy R, Schmidt AM. Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation. Ann Med 2009; 41: 408-422.
45. Osborne NJ, Ukoumunne OC, Wake M, Allen KJ. Prevalence of eczema and food allergy is associated with latitude in Australia. J Allergy Clin Immunol 2012; 129: 865-867.
46. Vassallo MF, Banerji A, Rudders SA, et al. Season of birth and food-induced anaphylaxis in Boston. Allergy 2010; 65: 1492-1493.
47. Mullins RJ, Clark S, Katelaris C, et al. Season of birth and childhood food allergy in Australia. Pediatr Allergy Immunol 2011; 22: 583-589.
48. Sharief S, Jariwala S, Kumar J, et al. Vitamin D levels and food and environmental allergies in the United States: results from the National Health and Nutrition Examination Survey. J Allergy Clin Immunol 2011; 127: 1195-1202.
49. Hirata M, Serizawa K, Aizawa K, et al. 22-Oxacalcitriol prevents progression of endothelial dysfunction through antioxidative effects in rats with type 2 diabetes and early-stage nephropathy. Nephrol Dial Transplant 2013; 28: 1166-1174.
50. Polidoro L, Properzi G, Marampon F, et al. Vitamin D protects human endothelial cells from H2O2 oxidant injury through the Mek/Erk-Sirt1 axis activation. J Cardiovasc Transl Res 2013; 6: 221-223.
51. Talmor Y, Golan E, Benchetrit S, et al. Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells. Am J Physiol Renal Physiol 2008; 294: F1059-F1064.
52. Berin MC, Zheng Y, Domaradzki M, et al. Role of TLR4 in allergic sensitization to food proteins in mice. Allergy 2006; 61: 64-71.
53. Ibrahim ZA, Armour CL, Phipps S, Sukkar MB. RAGE and TLRs: relatives, friends or neighbours? Mol Immunol 2013; 56: 739-744.
54. van Beijnum JR, Buurman WA, Griffioen AW. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 2008; 11: 91-99.
55. Tian J, Avalos AM, Mao SY, et al. Coyle AJ Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007; 8: 487-496.
56. Sirois CM, Jin T, Miller AL, et al. RAGE is a nucleic acid receptor that promotes inflammatory responses to DNA. J Exp Med 2013; 210: 2447-2463.
57. Ullah MA, Loh Z, Gan WJ, et al. Receptor for advanced glycation end products and its ligand high-mobility group box-1 mediate allergic airway sensitization and airway inflammation. J Allergy Clin Immunol 2014; 134: 440-450.
58. Ferguson GP, Tötemeyer S, MacLean MJ, Booth IR. Methylglyoxal production in bacteria: suicide or survival? Arch Microbiol 1998; 170: 209-218.
59. Cohen-Or I, Katz C, Ron EZ. AGEs secreted by bacteria are involved in the inflammatory response. PLoS One 2011; 6: e17974.
60. Mills DJ, Tuohy KM, Booth J, et al. Dietary glycated protein modulates the colonic microbiota towards a more detrimental composition in ulcerative colitis patients and nonulcerative colitis subjects. J Appl Microbiol 2008; 105: 706-714.
61. Kant R, Blom J, Palva A, et al. Comparative genomics of Lactobacillus. Microb Biotechnol 2011; 4: 323-332.
62. Lip Lin MY, Yen CL. Inhibition of lipid peroxidation by Lactobacillus acidophilus and Bifidobacterium longum. J Agric Food Chem 1999; 47: 3661-3664.
63. Corzo-Martinez M, Avila M, Moreno FJ, et al. Effect of milk protein glycation and gastrointestinal digestion on the growth of bifidobacteria and lactic acid bacteria. Int J Food Microbiol 2012; 153: 420-427.
64. Garcia AL, Otto B, Reich SC, et al. Arabinoxylan consumption decreases postprandial serum glucose, serum insulin and plasma total ghrelin response in subjects with impaired glucose tolerance. Eur J Clin Nutr 2007; 61: 334-341.
65. Milutinovic PS, Alcorn JF, Englert JM, et al. The receptor for advanced glycation end products is a central mediator of asthma pathogenesis. Am J Pathol 2012; 181: 1215-1225.
66. Taniguchi A, Miyahara XN, Waseda K, et al. Contrasting roles for the receptor for advanced glycation end-products on structural cells in allergic airway inflammation vs. airway hyperresponsiveness. Am J Physiol Lung Cell Mol Physiol 2015; 309: L789-L800.
67. Sukkar MB, Wood LG, Tooze M, et al. Soluble RAGE is deficient in neutrophilic asthma and COPD. Eur Respir J 2012; 39: 721-729.
68. Uribarri J, Woodruff S, Goodman S, et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 2010; 110: 911-916.
69. Clarke RE, Dordevic AL, Tan SM, et al. Dietary advanced glycation end products and risk factors for chronic disease: a systematic review of randomised controlled trials. Nutrients 2016; 8: 125.
70. Uribarri J, Peppa M, Cai W, et al. Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients. Am J Kidney Dis 2003; 42: 532-538.
71. Lué vano-Contreras C, Garay-Sevilla ME, Wrobel K, et al. Dietary advanced glycation end products restriction diminishes inflammation markers and oxidative stress in patients with type 2 diabetes mellitus. J Clin Biochem Nutr 2013; 52: 22-26.
72. Vlassara H, Li YM, Imani F, et al. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1995; 1: 634-646.
73. Li YM, Mitsuhashi T, Wojciechowicz D, et al. Molecular identity and cellular distribution of advanced glycation end product receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc Natl Acad Sci U S A 1996; 93: 11047-11052.
74. Ohgami N, Nagai R, Ikemoto M, et al. Nakayama H CD36, serves as a receptor for advanced glycation endproducts (AGE). JDiabetesComp 2002; 16: 56-59.
75. Sick E, Brehin S, André P, et al. Advanced glycation end products (AGEs) activate mast cells. Br J Pharmacol 2010; 161: 442-455.
76. Roy A, Ganesh G, Sippola H, et al. Mast cell chymase degrades the alarmins heat shock protein 70, biglycan, HMGB1, and interleukin-33 (IL-33) and limits danger-induced inflammation. J Biol Chem 2014; 289: 237-250.
77. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23: 479-490.
78. Cohen ES, Scott IC, Majithiya JB, et al. Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation. Nat Comms 2015; 6: 8327.
79. Bertheloot D, Latz E. HMGB1, IL-1a, IL-33 and S100 proteins: dual-function alarmins. Cell Mol Immunol 2017; 14: 43-64.
80. Smith PK, Masilamani M, Li XM, Sampson HA. The false alarm hypothesis: food allergy is associated with high dietary advanced glycation end-products and proglycating dietary sugars that mimic alarmins. J Allergy Clin Immunol 2017; 139: 429-437
81. Kearney J. Food consumption trends and drivers. Philos Trans R Soc Lond B Biol Sci 2010; 365: 2793-2807.
82. Yao D, Brownlee M. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 2010; 59: 249-255.
83. Steyn NP, Myburgh NG, Nel JH. Evidence to support a food-based dietary guideline on sugar consumption in South Africa. Bull World Health Organ 2003; 81: 599-608.
84. Gupta RS, Springston EE, Smith B, et al. Geographic variability of childhood food allergy in the United States. Clin Pediatr (Phila) 2012; 51: 856-861.
85. Kumar R, Ouyang F, Story RE, et al. Gestational diabetes, atopic dermatitis, and allergen sensitization in early childhood. J Allergy Clin Immunol 2009; 124: 1031-1038.
86. Mericq V, Piccardo C, Cai W, et al. Maternally transmitted and food-derived glycotoxins: a factor preconditioning the young to diabetes? Diabetes Care 2010; 33: 2232-2237.
87. Feeney M, Du Toit G, Roberts G, et al. Immune Tolerance Network LEAP Study Team. Impact of peanut consumption in the LEAP study: feasibility, growth, and nutrition. J Allergy Clin Immunol 2016; 138: 1108-1118.
88. Iannotti LL, Lutter CK, Stewart CP, et al. Eggs in early complementary feeding and child growth: a randomized controlled trial. Pediatrics 2017; pii: e20163459. doi: 10. 1542/peds. 2016-3459. [Epub ahead of print]
89. Coates ME, O'Donoghue PN. Milk allergy in infant germ-free rabbits. Nature 1967; 213: 307-308.
90. Sudo N, Sawamura S, Tanaka K, et al. The requirement of intestinal bacterial flora for the development of an IgE production system fully susceptible to oral tolerance induction. J Immunol 1997; 159: 1739-1745.
91. Patel R, Baker SS, Liu W, et al. Effect of dietary advanced glycation end products on mouse liver. PLoS One 2012; 7: e35143.
92. Lv L, Shao X, Chen H, et al. Genistein inhibits advanced glycation end product formation by trapping methylglyoxal. Chem Res Toxicol 2011; 24: 579-586.
93. Li X, Zheng T, Sang S, Lv L. Quercetin inhibits advanced glycation end product formation by trapping methylglyoxal and glyoxal. J Agric Food Chem 2014; 62: 12152-12158.
94. Okada Y, Oh-oka K, Nakamura Y, et al. Dietary resveratrol prevents the development of food allergy in mice. PLoS One 2012; 7: e44338.
95. Masilamani M, Wei J, Bhatt S, et al. Soybean isoflavones regulate dendritic cell function and suppress allergic sensitization to peanut. J Allergy Clin Immunol 2011; 128: 1242-1250.
96. Wu CH, Huang SM, Lin JA, Yen GC. Inhibition of advanced glycation endproduct formation by foodstuffs. Food Funct 2011; 2: 224-234.
97. Song F, Hurtado del Pozo C, Rosario R, et al. RAGE regulates the metabolic and inflammatory response to high-fat feeding in mice. Diabetes 2014; 63: 1948-1965.
98. Talmor Y, Golan E, Benchetrit S, et al. Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells. Am J Physiol Renal Physiol 2008; 294: F1059-F1064.
99. Choi KM, Han KA, Ahn HJ, et al. Effects of exercise on sRAGE levels and cardiometabolic risk factors in patients with type 2 diabetes: a randomized controlled trial. J Clin Endocrinol Metab 2012; 97: 3751-3758.